On March 19, 2026, Moleculin Biotech, Inc. filed a Form 8-K with the Securities and Exchange Commission (SEC) to disclose a corporate presentation and related financial exhibits. The filing includes Item 7.01, which pertains to Regulation FD Disclosure, indicating that the company is sharing information that may be material to investors. The attached presentation, labeled as Exhibit 99.1, is available on the company's website and aims to provide insights into the company's operations and strategic direction. Additionally, Item 9.01 of the filing includes financial statements and exhibits that further detail the company's financial position. This filing is considered administrative and does not indicate any significant changes in the company's financial health or operations. As such, it is not expected to have a noticeable impact on the stock price. The company continues to operate within its established framework, and this filing serves to keep investors informed of its ongoing activities and commitments.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.